Diabetes technology company Tandem Diabetes Care (NASDAQ: TNDM) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 13.8% year on year to $283.7 million. The company expects the full year’s revenue to be around $1.08 billion, close to analysts’ estimates. Its GAAP loss of $0.10 per share was 59.6% above analysts’ consensus estimates.

Is now the time to buy TNDM? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Tandem Diabetes delivered a quarter of strong operational execution, with management attributing growth to the expansion of its pharmacy channel in the U.S. and rapid scaling of direct commercial operations internationally. President and CEO John Sheridan highlighted that the company achieved record sales and pump shipments, both growing at double-digit rates, and pointed to increased demand for Tandem Mobi in the 12 countries where it is now available. Sheridan also noted that efficiency initiatives and business model changes helped drive significant margin expansion, underpinned by disciplined expense management and improvements in supply economics.

Looking ahead, Tandem Diabetes is focused on accelerating adoption of its PayGo pharmacy model and launching the Mobi Tubeless system, which management believes will drive greater access and recurring revenue. Sheridan emphasized that upcoming product launches, particularly those exclusive to the pharmacy channel, are expected to further expand market share and solidify the company’s position in both U.S. and international markets. CFO Leigh Vosseller pointed to a gradual but steady ramp in pharmacy adoption and underscored the importance of new product introductions and expanded formulary coverage as critical to achieving long-term growth objectives.

Key insights from management’s remarks

Management attributed the latest quarter’s results to the scaling of its pharmacy channel, strong international execution, and progress on new product launches, with several key updates shaping go-forward strategy.

• Pharmacy channel transition: The company’s PayGo pharmacy model in the U.S. reached about 15% of sales, with 50% formulary coverage, providing simplified access for customers and recurring supply revenue. Vosseller noted that while pharmacy adoption is scaling, the transition is happening more gradually than initially anticipated, impacting near-term sales mix but strengthening recurring revenue streams.
• Direct international expansion: Tandem expanded direct commercial operations to the U.K., Switzerland, Austria, and prepared for entry into France, now serving over 30% of its international installed base directly. Management credited this shift with improved pricing, stronger provider relationships, and higher margins, which contributed to the quarter’s outperformance in international markets.
• Product pipeline momentum: The company advanced its Mobi Tubeless system, designed to convert traditional pumps into tubeless devices, and initiated a global launch of AutoSoft Plus, a new infusion set. These launches are positioned as pharmacy-exclusive products, expected to accelerate channel adoption and expand addressable market segments.
• Margin expansion and efficiency: Gross margin improved, driven by pricing discipline, expanded direct operations, and supply chain efficiencies. Operating expenses grew modestly as management balanced commercial investments with ongoing cost control, resulting in positive operating leverage and the company’s fifth consecutive quarter of positive adjusted EBITDA.
• Leadership succession: CEO John Sheridan announced his retirement at year-end, with Jeannette Bankes set to succeed him. Robertson, Chair of the Board, highlighted Bankes’s extensive global medical technology experience and her alignment with Tandem’s mission-driven culture, positioning the company for continued execution and strategic clarity through the leadership transition.

Drivers of future performance

Tandem’s outlook hinges on scaling its pharmacy model, driving adoption of new products, and expanding international operations, while navigating structural revenue headwinds from business model shifts.

• Pharmacy adoption pace: Management expects the gradual transition to the pharmacy channel to remain a headwind for headline revenue growth in the near term, as pump adoption through pharmacy is outpacing supply conversions. However, higher recurring supply revenues and expanding formulary coverage are expected to improve long-term revenue visibility and margin mix as adoption accelerates.
• Product launches as catalysts: The upcoming launch of Mobi Tubeless and other pharmacy-only products is anticipated to drive customer conversion, new patient starts, and further engagement with payers and pharmacy benefit managers. Management views these products as key levers to increase market share, particularly as the company competes in the fastest-growing segment of the insulin pump market.
• International direct expansion: Ongoing efforts to transition key European markets to direct operations are expected to support higher pricing, improved customer access, and increased profitability. Management is watching for continued scaling of direct sales, further penetration of new geographies, and the ability to leverage direct market learnings to inform global strategy.

Catalysts in upcoming quarters

As we look ahead, our analysts will closely monitor (1) the pace of pharmacy channel adoption and the impact of exclusive product launches like Mobi Tubeless, (2) continued progress in transitioning international markets to direct operations and achieving higher pricing, and (3) execution of the CEO transition to ensure strategic continuity. Additional attention will be paid to regulatory milestones for the company’s pipeline and how supply chain improvements sustain margin gains.

Tandem Diabetes currently trades at $18.66, up from $17.99 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

High quality stocks for all market conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.